scholarly journals Estimation of Medical Expenditure Associated with Opioids usage in Chronic Non-Cancer Pain: a cross-sectional study based on Medical Expenditure Survey and Panel data

2015 ◽  
Vol 18 (3) ◽  
pp. A303
Author(s):  
Y. Zhang
Keyword(s):  
Panel Data ◽  
Cancer Pain ◽  
Cross Sectional Study ◽  
Medical Expenditure ◽  
Sectional Study ◽  
Cross Sectional ◽  
Expenditure Survey

scholarly journals Chronic non-cancer pain in primary care: an Italian cross-sectional study

2020 ◽  
Keyword(s):  
Primary Care ◽  
Chronic Pain ◽  
Cancer Pain ◽  
General Practitioners ◽  
Care Delivery ◽  
Cross Sectional Study ◽  
Italian Population ◽  
Sectional Study ◽  
Cross Sectional ◽  
Clinical Records

Chronic non-cancer pain is a complex health condition that affects more than a quarter of the Italian population who mainly refers to general practitioners and primary care for their treatment. There are little information on the epidemiological and clinical characteristics and types of treatments for these patients who suffer from chronic pain. The aim of the study was to provide epidemiological and clinical information about patients with chronic non-cancer pain who refers to GPs for their treatment. An observational, multicentre, cross-sectional study was carried out using retrospectively reviewed clinical records from 29 GPs. Some pharmacoeconomic aspects were also investigated. A total of 1,007 patients who had chronic pain were selected for the study. Chronic pain was more common in women than in men (ratio 2.7 : 1) (P = 0.002). With regard to incomes, the women earned less than the men (P = 0.017). The chronic pain was musculoskeletal (73.4%), mixed (21.4%), neuropathic (4.9%) and visceral (0.3%). More women than men had pain in two or more sites, and 33.5% of the patients reported more than one diagnosis that related to chronic pain. The general practitioners had prescribed nonsteroidal anti-inflammatory drugs for 71.8% of the cases, opioids for 16.9%, adjuvants for 9.0% and acetaminophen for 2.4%, and about pharmacoeconomic aspects, the total cost for the sample was € 111,331.42. Primary care is the essential frontline for patients who suffer from non-cancer pain. An interdisciplinary assessment and approach should start in primary care delivery to maximize the clinical outcomes.

scholarly journals Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e048528
Author(s):  
Thomas J Moore ◽  
Phillip W Wirtz ◽  
Stefan P Kruszewski ◽  
G Caleb Alexander
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Neurological Disorders ◽  
Cross Sectional Study ◽  
Population Characteristics ◽  
Medical Expenditure ◽  
Sectional Study ◽  
Cross Sectional ◽  
Age Cohorts ◽  
Cns Stimulants

ObjectiveTo assess the 5-year changes in the adult medical use of central nervous system (CNS) stimulants with higher risk of dependence and evaluate the population characteristics of users and their medical and/or neurological conditions.DesignCross-sectional study.SettingAnnual US Medical Expenditure Panel Survey, a stratified random sample of approximately 30 000 persons designed to produce national population estimates. It focuses on reported medical spending, medical services used, health status and prescription medications.ParticipantsAdults age 19 years and older who reported obtaining one or more prescriptions for amphetamine or methylphenidate products during two survey years, 2013 and 2018.Main outcomes measuresPrescriptions obtained, the specific stimulant product and annual treatment days of drug supplied.ResultsIn 2018, an estimated 4.1 million US adults (95% CI 3.4 million to 4.8 million) reported prescriptions for CNS stimulants, having filled a mean of 7.3 (95% CI 6.8 to 7.8) prescriptions with a mean of 226 (95% CI 210 to 242) days’ supply. Compared with 2013, the estimated number of adults reporting using CNS stimulants in 2018 increased by 1.8 million (95% CI 1.0 million to 2.7 million) or 79.8%. Most 2018 adult stimulant users reported taking psychoactive medication for one or more mental, behavioural or neurodevelopment disorders. Overall, 77.8% (95% CI 72.6% to 83.0%) reported some medication for adult attention deficit disorder, 26.8% (95% CI 22.2% to 31.5%) took medication for anxiety, 25.1% (95% CI 19.9% to 30.3%) for depression and 15.3% (95% CI 9.8% to 20.8%) indicated drug treatment for other mental or neurological disorders. Adult CNS stimulant use was higher in females, in younger age cohorts and among individuals of white race/ethnicity.ConclusionsAdult medical use of prescription stimulants increased markedly in 5 years and occurred in a population often reporting multiple mental or neurological disorders. Further action is needed to understand and manage this new resurgence in drugs with high risks of dependence.

scholarly journals Validation of the Japanese version of the barriers questionnaire II in cancer pain management: a cross-sectional study

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Naoki Sakakibara ◽  
Hiroko Komatsu ◽  
Mikako Takahashi ◽  
Hideko Yamauchi ◽  
Teruo Yamauchi ◽  
...  
Keyword(s):  
Pain Management ◽  
Cancer Pain ◽  
Japanese Version ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cancer Pain Management ◽  
Cross Sectional

scholarly journals Association of Self-Reported Functional Limitations among a National Community-Based Sample of Older United States Adults with Pain: A Cross-Sectional Study

2021 ◽  
Vol 10 (9) ◽  
pp. 1836
Author(s):  
David R. Axon ◽  
Darlena Le
Keyword(s):  
United States ◽  
Medical Expenditure Panel Survey ◽  
Functional Limitations ◽  
Functional Limitation ◽  
Cross Sectional Study ◽  
Medical Expenditure ◽  
Outcome Variable ◽  
Sectional Study ◽  
Cross Sectional ◽  
Logistic Regression Models

The characteristics of self-reported functional limitations among older United States (US) adults with pain are currently unknown. This cross-sectional study aimed to determine the characteristics associated with functional limitations among non-institutionalized older (≥50 years) US adults with pain using 2017 Medical Expenditure Panel Survey (MEPS) data. Eligible subjects were alive for the calendar year, aged ≥50 years, and experienced pain within the past four weeks. Hierarchical logistic regression models were utilized to determine significant characteristics associated with functional limitations (outcome variable; yes, no). Functional limitations included difficulty with bending, stooping, climbing stairs, grasping objects, lifting, reaching overhead, standing for long periods of time, or walking. Extrapolation of national data values was possible by adjusting for the complex MEPS design. We found approximately 22 million of the 57 million older US adults (≥50 years) who reported pain had a functional limitation in 2017. Characteristics associated with functional limitations included: gender, race, ethnicity, employment status, marital status, pain intensity, physical health, number of chronic conditions, and frequent exercise status. Knowledge of characteristics associated with functional limitations may provide an opportunity to identify and resolve gaps in patient care among this population.

scholarly journals Risk of opioid misuse in chronic non-cancer pain in primary care patients - a cross sectional study

2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Johannes Maximilian Just ◽  
Linda Bingener ◽  
Markus Bleckwenn ◽  
Rieke Schnakenberg ◽  
Klaus Weckbecker
Keyword(s):  
Primary Care ◽  
Cancer Pain ◽  
Cross Sectional Study ◽  
Opioid Misuse ◽  
Sectional Study ◽  
Cross Sectional ◽  
Primary Care Patients

Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer

2018 ◽  
Vol 94 (1116) ◽  
pp. 566-570 ◽  
Author(s):  
Caterina Magnani ◽  
Diana Giannarelli ◽  
Alice Calvieri ◽  
Ana Dardeli ◽  
Giovanni Eusepi ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Pharmacological Treatment ◽  
Cross Sectional Study ◽  
Terminal Cancer ◽  
Sectional Study ◽  
Cross Sectional ◽  
Breakthrough Cancer Pain ◽  
Short Acting ◽  
Tailored Treatment ◽  
Intravenous Morphine

BackgroundVarious options for the pharmacological treatment of breakthrough cancer pain (BTcP) are available. International guidelines on BTcP treatment are not univocal. A tailored treatment should be based on the assessment of different variables such as BTcP characteristics, oral mucositis, chronic rhinitis and a patient’s ability to take medication.ObjectiveThe goal of this study is to assess the relationship between these variables and the medication treatment for BTcP in a sample of patients with terminal cancer.MethodsA prospective, cross-sectional study was carried out among 1180 patients who were receiving palliative care programmes. Patients were recruited if they had a diagnosis of BTcP and had been prescribed rescue opioids. Variables that might influence the BTcP treatment were assessed.ResultsOne hundred and forty-nine eligible patients were enrolled; 59.1% of patients received short-acting oral morphine (OM), 27.5% transmucosal immediate-release fentanyl (TIRF) and 13.4% parenteral morphine for BTcP treatment. Short-acting OM prescription was related to background pain treatment with OM <60  mg daily (p<0.0001) and to home-care setting of assistance (p=0.004). Continuous intravenous morphine infusion and the presence of a vascular access were the main factors related to intravenous morphine prescription for BTcP. TIRF use was mainly related to background opioid dosage and the patient’s self-sufficiency in taking medication.ConclusionIn clinical practice, the factors that most influenced the pharmacological treatment for BTcP were baseline opioid dosage, setting of assistance and self-ability to take medication. Further research is needed to improve the knowledge on tailored BTcP treatment.

Sign in / Sign up

Export Citation Format

Share Document